Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Akorn Inc (AKRX)

Akorn Inc (AKRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,984
  • Shares Outstanding, K 133,152
  • Annual Sales, $ 682,430 K
  • Annual Income, $ -226,770 K
  • 60-Month Beta 1.15
  • Price/Sales 0.02
  • Price/Cash Flow 0.19
  • Price/Book N/A
Trade AKRX with:
  • Price/Earnings ttm 0.64
  • Earnings Per Share ttm 0.14
  • Most Recent Earnings 0.02 on 10/31/19
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0900 unch
on 05/29/20
0.3749 -75.99%
on 05/12/20
-0.1500 (-62.50%)
since 04/29/20
3-Month
0.0900 unch
on 05/29/20
1.3000 -93.08%
on 03/02/20
-1.0700 (-92.24%)
since 02/28/20
52-Week
0.0900 unch
on 05/29/20
5.4600 -98.35%
on 06/28/19
-4.0000 (-97.80%)
since 05/29/19

Most Recent Stories

More News
Ocular Inflammation Treatment Market Research 2020: Global Size, Growth, Trends, Outlook and Future Scope Analysis

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 4.40 (-3.93%)
AGN : 193.02 (+0.02%)
NVS : 90.24 (-1.46%)
PFE : 40.09 (-1.74%)
VRX.TO : 30.80 (-3.33%)
Dry Eye Syndrome Treatment Market Qualitative Data Research Report Expected Marvelous Growth by 2029 | Novartis AG, Allergan

A consciously conceived and designed business intelligence report titled Global by Manufacturers, Type, and Application, Forecast to 2029 by discloses a succinct analysis of the regional spectrum, market...

ABT : 107.53 (-0.57%)
AKRX : 0.0900 (-51.01%)
AGN : 193.02 (+0.02%)
BG : 60.78 (+2.48%)
NVS : 90.24 (-1.46%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market Research Report by Type, by Product Type, by End-Use Industry – Global Forecast to 2025 – Cumulative Impact of COVID-19

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 4.40 (-3.93%)
AGN : 193.02 (+0.02%)
NVS : 90.24 (-1.46%)
PFE : 40.09 (-1.74%)
VRX.TO : 30.80 (-3.33%)
Specialty Generic Drugs Market Size, Growth Research Analysis and Share to accumulate around $190.9 Bn by 2025

Global specialty generic drugs market Size, Share is poised to amass over US $190.9 billion by the year 2025, according to the latest research available at Market Study Report LLC, report provides extensively...

AKRX : 0.0900 (-51.01%)
ENDP : 5.46 (-1.97%)
PFE : 40.09 (-1.74%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market Research Services Industry to 2025 – COVID-19 Impact and Recovery

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 4.40 (-3.93%)
AGN : 193.02 (+0.02%)
NVS : 90.24 (-1.46%)
PFE : 40.09 (-1.74%)
VRX.TO : 30.80 (-3.33%)
[2020-2027] Conjunctivitis Treatment Market Worth USD 4.38 Billion at 3.7% CAGR; Management of Ocular Disorders to Augment Growth, says Fortune Business Insights(TM)

The global conjunctivitis treatment market size is set to gain traction from the rising technological advancements in the field of ophthalmology. Besides, the increasing discovery of new techniques of...

AKRX : 0.0900 (-51.01%)
NVS : 90.24 (-1.46%)
SNPHF : 16.2500 (unch)
Ocular Inflammation Treatment Market 2020 Analysis by Top Manufacturers -Allergan Plc., Cipla Ltd., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Alimera Sciences

AKRX : 0.0900 (-51.01%)
ALIM : 4.40 (-3.93%)
AGN : 193.02 (+0.02%)
NVS : 90.24 (-1.46%)
PFE : 40.09 (-1.74%)
VRX.TO : 30.80 (-3.33%)
The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4%

, /PRNewswire/ -- The topical drug delivery market is projected to reach by 2025 from in 2020, at a CAGR of 6.4% during the forecast period. The growth of this market is majorly driven by the high prevalence...

ACRS : 3.57 (+2.88%)
AKRX : 0.0900 (-51.01%)
AGN : 193.02 (+0.02%)
BAYRY : 14.5300 (unch)
CRRTF : 0.5647 (-1.74%)
GSK : 37.27 (-0.35%)
MRK : 81.45 (-0.46%)
NVS : 90.24 (-1.46%)
PRGO : 48.33 (+0.77%)
TARO : 70.89 (+0.72%)
TLGT : 0.5480 (+1.71%)
Global Ocular Inflammation Treatment Market 2020 Future Trend, Business Strategies, Revenue Value, Comprehensive Analysis and Forecast by 2025

offers a detailed sketch of each segment with sub-segment of the global market. The report depicts information regarding the drivers, restraints, opportunities, and trends affecting the global Ocular Inflammation...

AKRX : 0.0900 (-51.01%)
ALIM : 4.40 (-3.93%)
NVS : 90.24 (-1.46%)
PFE : 40.09 (-1.74%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market Report Reviews Drivers, Analysis, Share, Growth, Trends & Forecast to 2026

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 4.40 (-3.93%)
AGN : 193.02 (+0.02%)
NVS : 90.24 (-1.46%)
PFE : 40.09 (-1.74%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals,...

See More

Key Turning Points

2nd Resistance Point 0.2300
1st Resistance Point 0.1600
Last Price 0.0900
1st Support Level 0.0550
2nd Support Level 0.0200

See More

52-Week High 5.4600
Fibonacci 61.8% 3.4087
Fibonacci 50% 2.7750
Fibonacci 38.2% 2.1413
Last Price 0.0900
52-Week Low 0.0900

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar